Cheyenne Journal

Cholangiocarcinoma Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Basilea, Eisai, Roche, Incyte, Bayer, Janssen, Taiho Oncology, Agios Pharma

 Breaking News
  • No posts were found

Cholangiocarcinoma Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Basilea, Eisai, Roche, Incyte, Bayer, Janssen, Taiho Oncology, Agios Pharma

May 23
22:30 2023
Cholangiocarcinoma Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Basilea, Eisai, Roche, Incyte, Bayer, Janssen, Taiho Oncology, Agios Pharma
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Cholangiocarcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Cholangiocarcinoma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Cholangiocarcinoma Market. 

The Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Cholangiocarcinoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Cholangiocarcinoma and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Cholangiocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  Cholangiocarcinoma Pipeline Analysis


Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Cholangiocarcinoma Therapeutic Segment @

Cholangiocarcinoma Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Cholangiocarcinoma. Currently, ImmunoGen is leading the therapeutics market with its Cholangiocarcinoma drug candidates in the most advanced stage of clinical development.

The Leading Players in the Cholangiocarcinoma Therapeutics Market Include:

3D Medicines, AstraZeneca, Basilea Pharmaceutica, Boehringer Ingelheim, Bold Therapeutics, Bristol-Myers Squibb, Cellestia Biotech, Chia Tai Tianqing Pharmaceutical, CSPC Ouyi Pharmaceutical Co., Ltd., Eisai Inc., Elevation oncology, Eli Lilly and company, Elicio Therapeutics, Elucida Oncology, EMD Serono/Merck, Forma Therapeutics, Genoscience Pharma, Hutchison Medipharma Limited, Immunitor LLC, InnoCare Pharma, Intensity therapeutics, Janssen Pharmaceuticals, Jiangsu HengRui Medicine, Klus Pharma, Leap therapeutics, Merck Sharp & Dohme Corp., Newish Technology (Beijing) Co., Ltd., NGM Biopharmaceuticals, PCI Biotech AS, PCI Biotech AS, PureTech, QED Therapeutics, RedHill Biopharma, Relay Therapeutics, Senhwa Biosciences, Servier, Sirnaomics, Syndax Pharmaceuticals, Taiho Oncology, TCR2 therapeutics, TransThera Sciences, and others.

Cholangiocarcinoma Marketed and Emerging Therapies Covered in the Report Include:

  • Derazantinib: Basilea Pharmaceutica

  • E7090: Eisai

  • Entrectinib: Hoffmann-La Roche

  • Erdafitinib: Janssen Research and Development

  • Infigratinib: QED Therapeutics

  • Ivosidenib: Agios Pharmaceuticals

  • Larotrectinib: Loxo Oncology

  • Melphalan Hydrochloride: Delcath Systems

  • Pembrolizumab: Merck Sharp & dohme

  • Pemigatinib: Incyte Corporation

  • Regorafenib: Bayer

  • TAS-120: Taiho Oncology

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Cholangiocarcinoma Current Treatment Patterns

4. Cholangiocarcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Cholangiocarcinoma Late Stage Products (Phase-III)

7. Cholangiocarcinoma Mid-Stage Products (Phase-II)

8. Cholangiocarcinoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cholangiocarcinoma Discontinued Products

13. Cholangiocarcinoma Product Profiles

14. Key Companies in the Cholangiocarcinoma Market

15. Key Products in the Cholangiocarcinoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Cholangiocarcinoma Unmet Needs

18. Cholangiocarcinoma Future Perspectives

19. Cholangiocarcinoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Asthma Diagnostic Devices Market

“Asthma Diagnostic Devices Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Asthma Diagnostic Devices market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Asthma Diagnostic Devices Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States